These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 26232000)

  • 41. Efficacy and safety of switching to abacavir/lamivudine (ABC/3TC) plus rilpivirine (RPV) in virologically suppressed HIV-infected patients on HAART.
    Palacios R; Pérez-Hernández IA; Martínez MA; Mayorga ML; González-Domenech CM; Omar M; Olalla J; Romero A; Romero JM; Pérez-Camacho I; Hernández-Quero J; Santos J
    Eur J Clin Microbiol Infect Dis; 2016 May; 35(5):815-9. PubMed ID: 26879392
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Usefulness of therapeutic drug monitoring of rilpivirine and its relationship with virologic response and resistance in a cohort of naive and pretreated HIV-infected patients.
    Néant N; Lê MP; Bouazza N; Gattacceca F; Yazdanpanah Y; Dhiver C; Bregigeon S; Mokhtari S; Peytavin G; Tamalet C; Descamps D; Lacarelle B; Solas C
    Br J Clin Pharmacol; 2020 Dec; 86(12):2404-2413. PubMed ID: 32374049
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dolutegravir-based dual maintenance regimens combined with lamivudine/emtricitabine or rilpivirine: risk of virological failure in a real-life setting.
    Deschanvres C; Reynes J; Lamaury I; Rey D; Palich R; Bani-Sadr F; Robineau O; Duvivier C; Hocqueloux L; Cuzin L; Joly V; Raffi F; Cabie A; Allavena C;
    J Antimicrob Chemother; 2021 Dec; 77(1):196-204. PubMed ID: 34651192
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and improvement of lipid profile after switching to rilpivirine in resource limited setting: real life clinical practice.
    Gatechompol S; Avihingsanon A; Apornpong T; Han WM; Kerr SJ; Ruxrungtham K
    AIDS Res Ther; 2019 Apr; 16(1):7. PubMed ID: 30953533
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment.
    Wilkins EL; Cohen CJ; Trottier B; Esser S; Smith DE; Haas B; Brinson C; Garner W; Chuck S; Thorpe D; De-Oertel S
    AIDS Care; 2016; 28(3):401-8. PubMed ID: 26489045
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lipid changes and tolerability in a cohort of adult HIV-infected patients who switched to rilpivirine/emtricitabine/tenofovir due to intolerance to previous combination ART: the PRO-STR study.
    Ocampo A; Domingo P; Fernández P; Diz J; Barberá JR; Sepúlveda MA; Salgado X; Rodriguez M; Santos J; Yzusqui M; Mayorga MI; Lorenzo JF; Bahamonde A; Bachiller P; Martínez E; Rozas N; Torres C; Muñoz A; Casado A; Podzamczer D
    J Antimicrob Chemother; 2018 Aug; 73(8):2171-2176. PubMed ID: 29788066
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Off-label use of rilpivirine in combination with emtricitabine and tenofovir in HIV-1-infected pediatric patients: A multicenter study.
    Falcon-Neyra L; Palladino C; Navarro Gómez ML; Soler-Palacín P; González-Tomé MI; De Ory SJ; Frick MA; Fortuny C; Noguera-Julian A; Moreno EB; Santos JL; Olbrich P; López-Cortés LF; Briz V; Neth O;
    Medicine (Baltimore); 2016 Jun; 95(24):e3842. PubMed ID: 27310962
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of a switch to rilpivirine-based regimens in treatment-experienced HIV-1-infected patients: a cohort study.
    Gazaignes S; Resche-Rigon M; Gatey C; Yang C; Denis B; Fonsart J; Desseaux K; Guionie M; Rozenbaum W; Delaugerre C; Molina JM
    Antivir Ther; 2016; 21(4):329-36. PubMed ID: 26566057
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Initiation of rilpivirine, tenofovir and emtricitabine (RPV/TDF/FTC) regimen in 363 patients with virological vigilance assessment in 'real life'.
    Amiel C; Schneider V; Guessant S; Hamidi M; Kherallah K; Lebrette MG; Chas J; Lependeven C; Pialoux G
    J Antimicrob Chemother; 2014 Dec; 69(12):3335-9. PubMed ID: 25114163
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hepatic Safety of Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate Fixed-Dose Single-Tablet Regimen in HIV-Infected Patients with Active Hepatitis C Virus Infection: The hEPAtic Study.
    Neukam K; Espinosa N; Collado A; Delgado-Fernández M; Jiménez-Aguilar P; Rivero-Juárez A; Hontañón-Antoñana V; Gómez-Berrocal A; Ruiz-Morales J; Merino D; Carrero A; Téllez F; Ríos MJ; Hernández-Quero J; de Lagarde-Sebastián M; Pérez-Camacho I; Vera-Méndez F; Macías J; Pineda JA;
    PLoS One; 2016; 11(5):e0155842. PubMed ID: 27195797
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials.
    Tebas P; Sension M; Arribas J; Duiculescu D; Florence E; Hung CC; Wilkin T; Vanveggel S; Stevens M; Deckx H;
    Clin Infect Dis; 2014 Aug; 59(3):425-34. PubMed ID: 24729492
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Switching protease inhibitors to rilpivirine in HIV-positive individuals with complete viral suppression and without prior HIV drug resistance in a resource-limited setting: a randomized controlled trial.
    Palanuphap K; Sungkanuparph S
    J Int AIDS Soc; 2020 Apr; 23(4):e25462. PubMed ID: 32277868
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Triple-combination rilpivirine, emtricitabine, and tenofovir (Complera™/Eviplera™) in the treatment of HIV infection.
    Bernardini C; Maggiolo F
    Patient Prefer Adherence; 2013; 7():531-42. PubMed ID: 23814462
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine.
    Gallien S; Charreau I; Nere ML; Mahjoub N; Simon F; de Castro N; Aboulker JP; Molina JM; Delaugerre C
    J Antimicrob Chemother; 2015 Feb; 70(2):562-5. PubMed ID: 25344807
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
    Manfredi R; Calza L
    AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain: The TRIP study.
    Pedrol E; Caro-Murillo AM; Castaño MA; Riera M; Olalla J; Domingo P; Arazo P; Gómez-Sirvent JL; Pulido F; Romero-Palacios A; Aguirrebengoa K; Vera F; Ferrer P; Blanco Ramos JR
    HIV Clin Trials; 2015; 16(1):43-8. PubMed ID: 25777189
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Doravirine/lamivudine/tenofovir disoproxil fumarate in virologically suppressed people living with HIV: A real-life experience.
    Calza L; Colangeli V; Pensalfine G; Appolloni L; Vitale S; Bon I; Viale P
    Int J STD AIDS; 2023 Dec; 34(14):1018-1023. PubMed ID: 37565832
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Successful switch to rilpivirine/tenofovir/emtricitabine in HIV-1-infected patients with an isolated K103N mutation acquired during prior nonnucleoside reverse transcriptase inhibitor therapy.
    Rokx C; Verbon A; Rijnders BJ
    HIV Med; 2014 Nov; 15(10):611-4. PubMed ID: 24738660
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and safety of atazanavir-ritonavir plus abacavir-lamivudine or tenofovir-emtricitabine in patients with hyperlipidaemia switched from a stable protease inhibitor-based regimen including one thymidine analogue.
    Calza L; Manfredi R; Colangeli V; Pocaterra D; Rosseti N; Pavoni M; Chiodo F
    AIDS Patient Care STDS; 2009 Sep; 23(9):691-7. PubMed ID: 19739937
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety of a once-daily single-tablet regimen of tenofovir, lamivudine, and efavirenz assessed at 144 weeks among antiretroviral-naïve and experienced HIV-1-infected Thai adults.
    Avihingsanon A; Maek-A-Nantawat W; Gatechompol S; Sapsirisavat V; Thiansanguankul W; Sophonphan J; Thammajaruk N; Ubolyam S; Burger DM; Ruxrungtham K
    Int J Infect Dis; 2017 Aug; 61():89-96. PubMed ID: 28627427
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.